Mironid Extends Series A Round Raising £35 Million to Date for Development of First-In-Class Small Molecules to Treat Life-Threatening Hereditary Kidney Disease
September 13, 2023
Glasgow, Scotland – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a life-threatening hereditary kidney